The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Adamyan L.V.

Russian University of Medicine;
National Medical Research Center for Obstetrics, Gynecology and Perinatology Named After Academician V.I. Kulakov

Nosov V.B.

Russian University of Medicine

Stepanian A.A.

Academia of Women’s Health and Endoscopic Surgery

Fertility-sparing treatment in cancer patients: how can we help in the 21st century?

Authors:

Adamyan L.V., Nosov V.B., Stepanian A.A.

More about the authors

Journal: Russian Journal of Human Reproduction. 2024;30(1): 26‑63

DOI: 10.17116/repro20243001126

Views: 1801

Downloaded: 115

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Adamyan LV, Nosov VB, Stepanian AA. Fertility-sparing treatment in cancer patients: how can we help in the 21st century?. Russian Journal of Human Reproduction. 2024;30(1):26‑63. (In Russ.)
https://doi.org/10.17116/repro20243001126

Подписка 2025 (Russian Journal of Human Reproduction)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Modern operative gyne­cology in geriatric patients. Russian Journal of Human Reproduction. 2024;(1):10-25
Histological changes in the endo­metrium during intrauterine use of platelet-rich plasma (PRP) in assi­sted reproductive technology programs. Russian Journal of Human Reproduction. 2024;(1):82-91
Differential diagnosis of volu­metric formation of the pelvic organs and abdo­minal cavity in the practice of an obstetrician-gynecologist and neurosurgeon using the example of sero­zocele (seroma). Russian Journal of Human Reproduction. 2024;(1):116-121
Mode­lling and prevention of postoperative adhe­sions in gynaecological and pelvic surgery in expe­riment: morphological and ultrastructural features. Russian Journal of Human Reproduction. 2024;(2):42-50
Opti­mal prevention of VTE in cancer surgery patients with impaired renal function. Piro­gov Russian Journal of Surgery. 2024;(1):119-126
Limi­tations and possibilities of treatment of patients with infe­rtility against the background of multiple scle­rosis disease during the COVID-19 pandemic. Russian Bulletin of Obstetrician-Gynecologist. 2024;(1):83-87
Arti­ficial inte­lligent systems in the deve­lopment of assi­sted reproductive technologies. Russian Bulletin of Obstetrician-Gynecologist. 2024;(2):19-29
Unco­ntrolled inhi­bition of checkpoints. P.A. Herzen Journal of Onco­logy. 2024;(2):67-73
Pre-rehabilitation of onco­logical patients before exte­nsive abdo­minal and thoracic surgery: a lite­rature review. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(2):46-56

As of 2020, 19.000.000 new cancer cases were detected worldwide of which 5% (950.000) were found in patients under 40 years of age at the time of diagnosis. All of them can be seen as potential candidates for a fertility-sparing treatment prior, during or after main canther therapy. Among female patients of this group breast cancer, cervical cancer, melanoma and hematologic malignancies are most prevalent. This article reviews proven oncologically safe surgical and conservative fertility-sparing approaches for each individual disease as well as embryological techniques available to achieve pregnancies.

Keywords:

oncofertility
oncology
HRT
surgery

Authors:

Adamyan L.V.

Russian University of Medicine;
National Medical Research Center for Obstetrics, Gynecology and Perinatology Named After Academician V.I. Kulakov

Nosov V.B.

Russian University of Medicine

Stepanian A.A.

Academia of Women’s Health and Endoscopic Surgery

Received:

21.01.2024

Accepted:

22.01.2024

List of references:

  1. Santaballa A, Márquez-Vega C, Rodríguez-Lescure Á, Rovirosa Á, Vázquez L, Zeberio-Etxetxipia I, Andrés M, Bassas L, Ceballos-Garcia E, Domingo J, Manau-Trullas D. Multidisciplinary consensus on the criteria for fertility preservation in cancer patients. Clinical and Translational Oncology. 2022;24(2):227-243.  https://doi.org/10.1007/s12094-021-02699-2
  2. Adamyan LV, Jordania KI, Payanidi YuG, Tyrsina EG. Possibilities of rehabilitation in cancer patients to preserve their reproductive function. Opuxoli zhenskoj reproduktivnoj sistemyt. 2010;4:118-122. (In Russ.). https://doi.org/10.17650/1994-4098-2010-0-4-118-122
  3. Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, Wallace WH, Wang ET, Loren AW. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology. 2018;36(19):1994-2001. https://doi.org/10.1200/JCO.2018.78.1914
  4. Lambertini M, Peccatori FA, Demeestere I, Amant F, Wyns C, Stukenborg JB, Paluch-Shimon S, Halaska MJ, Uzan C, Meissner J, von Wolff M, Anderson RA, Jordan K. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines. Annals of Oncology. 2020;31(12): 1664-1678. https://doi.org/10.1016/j.annonc.2020.09.006
  5. Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HA Jr, Peccatori FA, Costa M, Revelli A, Salvagno F, Gennari A, Ubaldi FM, La Sala GB, De Stefano C, Wallace WH, Partridge AH, Anserini P. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Medicine. 2016;14:1.  https://doi.org/10.1186/s12916-015-0545-7
  6. Levine JM, Kelvin JF, Quinn GP, Gracia CR. Infertility in reproductive-age female cancer survivors. Cancer. 2015;121(10):1532-1539. https://doi.org/10.1002/cncr.29181
  7. Kiseleva MV, Abakushina EV, Tsyb AF. Assisted reproductive technologies in preserving the reproductive function of cancer patients. Opuxoli zhenskoj reproduktivnoj sistemyt. 2009;(1-2):118-122. (In Russ.).
  8. Chan JL, Letourneau J, Salem W, Cil AP, Chan SW, Chen LM, Rosen MP. Regret around fertility choices is decreased with pre-treatment counseling in gynecologic cancer patients. Journal of Cancer Survivorship. 2017;11(1):58-63.  https://doi.org/10.1007/s11764-016-0563-2
  9. Oktem O, Oktay K. A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. Cancer Research. 2007;67(21):10159-10162. https://doi.org/10.1158/0008-5472.CAN-07-2042
  10. Rodriguez-Wallberg KA, Anastacio A, Vonheim E, Deen S, Malmros J, Borgström B. Fertility preservation for young adults, adolescents, and children with cancer. Upsala Journal of Medical Sciences. 2020;125(2):112-120.  https://doi.org/10.1080/03009734.2020.1737601
  11. Klinicheskie rekomendacii. Pogranichnyte opuxoli yaichnikov. Odobreno Nauchnytm Sovetom Ministerstva zdravooxraneniya Rossijskoj Federacii. 2020. Accessed January 17, 2024. (In Russ.). https://oncology-association.ru/wp-content/uploads/2020/09/pogranichnye_opuholi_jaichnikov.pdf
  12. Klinicheskie rekomendacii. Rak tela matki i sarkomyt matki. 2021. Odobreno Nauchno-prakticheskim Sovetom Ministerstva zdravooxraneniya Rossijskoj Federacii. Accessed January 17, 2024. (In Russ.). https://oncology-association.ru/wp-content/uploads/2021/02/rak-tela-matki-i-sarkomy-matki-2021.pdf
  13. Volochaeva MV, Shmakov RG, Demina EA. Influence of chemotherapy on reproductive system: methods of protection and preservation of ovarian function. Klinicheskaya onkogematologiya. 2014; 7(2):114-121. (In Russ.).
  14. Martinez F. Update on fertility preservation from the Barcelona International Society for Fertility Preservation-ESHRE-ASRM 2015 expert meeting: indications, results and future perspectives. Human Reproduction. 2017;32(9):1802-1811. https://doi.org/10.1093/humrep/dex218
  15. Schover LR. Premature Ovarian Failure and Its Consequences: Vasomotor Symptoms, Sexuality, and Fertility. Journal of Clinical Oncology. 2008;26(5):753-758.  https://doi.org/10.1200/JCO.2007.14.1655
  16. Gerber B, Dieterich M, Müller H, Reimer T. Controversies in preservation of ovary function and fertility in patients with breast cancer. Breast Cancer Research and Treatment. 2008;108(1):1-7.  https://doi.org/10.1007/s10549-007-9572-1
  17. Gerber B, Heintze K, Stubert J, Dieterich M, Hartmann S, Stachs A, Reimer T. Axillary lymph node dissection in early-stage invasive breast cancer: is it still standard today? Breast Cancer Research and Treatment. 2011;128(3):613-624.  https://doi.org/10.1007/s10549-011-1532-0
  18. Dobrokhotova YuE, Morozova KV. Opportunities for ovarian reserve preservation in the treatment of oncological diseases. Ginekologiya. 2019;6:21-25.(In Russ.). https://doi.org/10.26442/20795696.2019.6.190709
  19. Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, Giordano M, Garrone O, Pronzato P, Bighin C, Levaggi A, Giraudi S, Cresti N, Magnolfi E, Scotto T, Vecchio C, Venturini M. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapyinduced early menopause in premenopausal women with breast cancer: A randomized trial. JAMA. 2011;306:269-276.  https://doi.org/10.1001/jama.2011.991
  20. Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, Giordano M, Garrone O, Levaggi A, Poggio F, Giraudi S, Bighin C, Vecchio C, Sertoli MR, Pronzato P, Del Mastro L. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: A randomized clinical trial. JAMA. 2015;314:2632-2640. https://doi.org/10.1001/jama.2015.17291
  21. Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biology of Reproduction. 1995;52(2):365-372.  https://doi.org/10.1095/biolreprod52.2.365
  22. Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M, Boni L, Unger JM, Anderson RA, Mehta K, Minton S, Poggio F, Albain KS, Adamson DJA, Gerber B, Cripps A, Bertelli G, Seiler S, Ceppi M, Partridge AH, Del Mastro L. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. Journal of Clinical Oncology. 2018;36(19):1981-1990. https://doi.org/10.1200/JCO.2018.78.0858
  23. Key Statistics for Cervical Cancer. American Cancer Society, 2023.
  24. Axel EM, Vinogradova NN. Statistics of malignant neoplasms of female reproductive organs. Onkoginekologiya. 2018;3:64-78. (In Russ.).
  25. Mota F. Microinvasive squamous carcinoma of the cervix: treatment modalities. Acta Obstetricia et Gynecologica Scandinavica. 2003; 82(6):505-509.  https://doi.org/10.1034/j.1600-0412.2003.00124.x
  26. Ostör AG. Pandora’s box or Ariadne’s thread? Definition and prognostic significance of microinvasion in the uterine cervix. Squamous lesions. Pathology Annual. 1995;30(2):103-136. 
  27. Abu-Rustum NR, Neubauer N, Sonoda Y, Park KJ, Gemignani M, Alektiar KM, Tew W, Leitao MM, Chi DS, Barakat RR. Surgical and pathologic outcomes of fertility-sparing radical abdominal trachelectomy for FIGO stage IB1 cervical cancer. Gynecological Oncology. 2008;111(2):261-264.  https://doi.org/10.1016/j.ygyno.2008.07.002
  28. Beiner ME, Hauspy J, Rosen B, Murphy J, Laframboise S, Nofech-Mozes S, Ismiil N, Rasty G, Khalifa MA, Covens A. Radical vaginal trachelectomy vs. radical hysterectomy for small early stage cervical cancer: a matched case-control study. Gynecological Oncology. 2008;110(2):168-171.  https://doi.org/10.1016/j.ygyno.2008.04.027
  29. Plante M, Gregoire J, Renaud MC, Roy M. The vaginal radical trachelectomy: an update of a series of 125 cases and 106 pregnancies. Gynecological Oncology. 2011;121(2):290-297.  https://doi.org/10.1016/j.ygyno.2010.12.345
  30. Machida H, Mandelbaum RS, Mikami M, Enomoto T, Sonoda Y, Grubbs BH, Paulson RJ, Roman LD, Wright JD, Matsuo K. Characteristics and outcomes of reproductive-aged women with early-stage cervical cancer: trachelectomy vs hysterectomy. American Journal of Obstetrics and Gynecology. 2018;461.e1-18.  https://doi.org/10.1016/j.ajog.2018.08.020
  31. Li J, Wu X, Li X, Ju X. Abdominal radical trachelectomy: is it safe for IB1 cervical cancer with tumors >2 cm? Gynecologic Oncology. 2013;131:87-92.  https://doi.org/10.1016/j.ygyno.2013.07.079
  32. Cao DY, Yang JX, Wu XH, Chen YL, Li L, Liu KJ, Cui MH, Xie X, Wu YM, Kong BH, Zhu GH, Xiang Y, Lang JH, Shen K. Comparisons of vaginal and abdominal radical trachelectomy for early-stage cervical cancer: preliminary results of a multi-center research in China. British Journal of Cancer. 2013;109:2778-2782. https://doi.org/10.1038/bjc.2013.656
  33. Park JY, Joo WD, Chang SJ, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. Long-term outcomes after fertility-sparing laparoscopic radical trachelectomy in young women with early-stage cervical cancer: an Asian Gynecologic Cancer Group (AGCG) study. Journal of Surgical Oncology. 2014;110:252-257.  https://doi.org/10.1002/jso.23631
  34. Plante M. Bulky Early-Stage Cervical Cancer (2-4 cm Lesions): Upfront Radical Trachelectomy or Neoadjuvant Chemotherapy Followed by Fertility-Preserving Surgery: Which Is the Best Option? International Journal of Gynecological Cancer. 2015;25(4):722-728.  https://doi.org/10.1097/IGC.0000000000000410
  35. Schmeler KM, Pareja R, Lopez Blanco A, Humberto Fregnani J, Lopes A, Perrotta M, Tsunoda AT, Cantú-de-León DF, Ramondetta LM, Manchana T, Crotzer DR, McNally OM, Riege M, Scambia G, Carvajal JM, Di Guilmi J, Rendon GJ, Ramalingam P, Fellman BM, Coleman RL, Frumovitz M, Ramirez PT. ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer. International Journal of Gynecological Cancer. 2021; 31(10):1317-1325. https://doi.org/10.1136/ijgc-2021-002921
  36. Einstein MH, Park KJ, Sonoda Y, Carter J, Chi DS, Barakat RR, Abu-Rustum NR. Radical vaginal versus abdominal trachelectomy for stage IB1 cervical cancer: a comparison of surgical and pathologic outcomes. Gynecologic Oncology. 2009;112(1):73-77.  https://doi.org/10.1016/j.ygyno.2008.09.007
  37. Nezhat C, Roman RA, Rambhatla A, Nezhat F. Reproductive and oncologic outcomes after fertility-sparing surgery for early stage cervical cancer: a systematic review. Fertility and Sterility. 2020;113(4): 685-703.  https://doi.org/10.1016/j.fertnstert.2020.02.003
  38. Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, Buda A, Yan X, Shuzhong Y, Chetty N, Isla D, Tamura M, Zhu T, Robledo KP, Gebski V, Asher R, Behan V, Nicklin JL, Coleman RL, Obermair A. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. The New England Journal of Medicine. 2018;379(20):1895-1904. https://doi.org/10.1056/NEJMoa1806395
  39. Abu-Rustum NR, Yashar CM, Arend R, Barber E, Bradley K, Brooks R, Campos SM, Chino J, Chon HS, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Gaillard S, Giuntoli R, Glaser S, Holmes J, Howitt BE, Lea J, Mantia-Smaldone G, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Podoll M, Rodabaugh K, Salani R, Schorge J, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wyse E, McMillian NR, Aggarwal S, Espinosa S. NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024. Journal of the National Comprehensive Cancer Network: JNCCN. 2023;21(12):1224-1233. https://doi.org/10.6004/jnccn.2023.0062
  40. Lv Z, Wang YY, Wang YW, He JJ, Lan WW, Peng JY, Lin ZH, Zhu RF, Zhou J, Chen ZQ, Jiang YH, Yuan Y, Xiong J. A meta-analysis of treatment for early-stage cervical cancer: open versus minimally invasive radical trachelectomy. BMC Pregnancy and Childbirth. 2023;23(1):727.  https://doi.org/10.1186/s12884-023-06036-z
  41. Johansen G, Lönnerfors C, Falconer H, Persson J. Reproductive and oncologic outcome following robot-assisted laparoscopic radical trachelectomy for early stage cervical cancer. Gynecologic Oncology. 2016;141(1):160-165.  https://doi.org/10.1016/j.ygyno.2016.01.028
  42. Kenter GG, Greggi S, Vergote I, Katsaros D, Kobierski J, van Doorn H, Landoni F, van der Velden J, Reed N, Coens C, van Luijk I, Colombo N, Steen-Banasik EV, Ottevanger N, Casado A; EORTC-55994 Study Group. Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994. Journal of Clinical Oncology. 2023;41(32):5035-5043. https://doi.org/10.1200/JCO.22.02852
  43. Gwacham NI, McKenzie ND, Fitzgerald ER, Ahmad S, Holloway RW. Neoadjuvant chemotherapy followed by fertility sparing surgery in cervical cancers size 2-4 cm; emerging data and future perspectives. Gynecologic Oncology. 2021;162(3):809-815.  https://doi.org/10.1016/j.ygyno.2021.06.006
  44. Bentivegna E, Maulard A, Pautier P, Chargari C, Gouy S, Morice P. Fertility results and pregnancy outcomes after conservative treatment of cervical cancer: a systematic review of the literature. Fertility and Sterility. 2016;106(5):1195-1211.e5.  https://doi.org/10.1016/j.fertnstert.2016.06.032
  45. Salman MC, Ozgul N, Yuce K. Widespread recurrence 7 years after radical abdominal trachelectomy for early cervical adenocarcinoma. Case Reports in Obstetrics and Gynecology. 2015;2015:517496. https://doi.org/10.1155/2015/517496
  46. Li X, Li J, Jiang Z, Xia L, Ju X, Chen X, Wu X. Oncological results and recurrent risk factors following abdominal radical trachelectomy: an updated series of 333 patients. BJOG. 2019;126(9):1169-1174. https://doi.org/10.1111/1471-0528.15621
  47. Cai J, He X, Wang H, Dong W, Zhang Y, Zhao J, Willborn KC, Huang B, Wang Z, Jiang P. Topographic distribution of lymph node metastasis in patients with stage IB1 cervical cancer: an analysis of 8314 lymph nodes. Radiation Oncology. 2021;16(1):54. 
  48. Cao L, Kong W, Li J, Song D, Jin B, Liu T, Han C. Analysis of Lymph Node Metastasis and Risk Factors in 975 Patients with FIGO 2009 Stage IA-IIA Cervical Cancer. Gynecologic and Obstetric Investigation. 2023;88(1):30-36.  https://doi.org/10.1159/000527712
  49. Li R, Lu ST, Si JG, Liu B, Wang H, Mei YY, Linghu H. Prognostic value of responsiveness of neoadjuvant chemotherapy before surgery for patients with stage IB(2)/IIA(2) cervical cancer. Gynecologic Oncology. 2013;128:524Y529. https://doi.org/10.1016/j.ygyno.2012.11.006
  50. Rendón GJ, Lopez Blanco A, Aragona A, Saadi JM, Di Guilmi J, Arab Eblen C, Heredia Muñoz F, Pareja R. Oncological and obstetrical outcomes after neo-adjuvant chemotherapy followed by fertility-sparing surgery in patients with cervical cancer ≥2 cm. International Journal of Gynecological Cancer. 2021;31(3):462-467.  https://doi.org/10.1136/ijgc-2020-002076
  51. Cibula D, Pötter R, Planchamp F, Avall-Lundqvist E, Fischerova D, Haie Meder C, Köhler C, Landoni F, Lax S, Lindegaard JC, Mahantshetty U, Mathevet P, McCluggage WG, McCormack M, Naik R, Nout R, Pignata S, Ponce J, Querleu D, Raspagliesi F, Rodolakis A, Tamussino K, Wimberger P, Raspollini MR. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer. International Journal of Gynecological Cancer. 2018;28(4):641-655.  https://doi.org/10.1097/IGC.0000000000001216
  52. Zusterzeel PLM, Aarts JWM, Pol FJM, Ottevanger PB, van Ham MAPC. Neoadjuvant Chemotherapy Followed by Vaginal Radical Trachelectomy as Fertility-Preserving Treatment for Patients with FIGO 2018 Stage 1B2 Cervical Cancer. Oncologist. 2020;25(7):e1051-e1059. https://doi.org/10.1634/theoncologist.2020-0063
  53. Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Giuntoli R, Han E, Huh WK, Lurain Iii JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Sisodia R, Tillmanns T, Ueda S, Urban R, Wyse E, McMillian NR, Motter AD. NCCN Guidelines Insights: Cervical Cancer, Version 1.2020. Journal of the National Comprehensive Cancer Network. 2022;18(6):660-666.  https://doi.org/10.6004/jnccn.2020.0027
  54. Lissoni AA, Colombo N, Pellegrino A, Parma G, Zola P, Katsaros D, Chiari S, Buda A, Landoni F, Peiretti M, Dell’anna T, Fruscio R, Signorelli M, Grassi R, Floriani I, Fossati R, Torri V, Rulli E. A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02. Italian Collaborative Study. Annals of Oncology. 2009;20(4):660-665.  https://doi.org/10.1093/annonc/mdn690
  55. Lorusso D, Petrelli F, Coinu A, Raspagliesi F, Barni S. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecologic Oncology. 2014;133(1):117-123.  https://doi.org/10.1016/j.ygyno.2014.01.042
  56. Theofanakis C, Koulakmanidis AM, Prodromidou A, Haidopoulos D, Rodolakis A, Thomakos N. Fertility-Sparing Treatment for Young Patients with Early-Stage Cervical Cancer: A Dawn of a New Era. Frontiers in surgery. 2022;9:867993. https://doi.org/10.3389/fsurg.2022.867993
  57. Buda A, Borghese M, Puppo A, Perotto S, Novelli A, Borghi C, Olearo E, Tripodi E, Surace A, Bar E, Scambia G, Fanfani F. Neoadjuvant Chemotherapy Prior Fertility-Sparing Surgery in Women with FIGO 2018 Stage IB2 Cervical Cancer: A Systematic Review. Cancers. 2022;14(3):797.  https://doi.org/10.3390/cancers14030797
  58. Laios A, Otify M, Papadopoulou A, Gallos ID, Ind T. Outcomes of ovarian transposition in cervical cancer; an updated meta-analysis. BMC Womens Health. 2022;22(1):305.  https://doi.org/10.1186/s12905-022-01887-8
  59. Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, Quinn G, Wallace WH, Oktay K; American Society of Clinical Oncology. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology. 2013;31(19):2500-2510. https://doi.org/10.1200/JCO.2013.49.2678
  60. Kotsopoulos J, Narod SA. Prophylactic salpingectomy for the prevention of ovarian cancer: Who should we target? International Journal of Cancer. 2020;147(5):1245-1251. https://doi.org/10.1002/ijc.32916
  61. Sella T, Mironov S, Hricak H. Imaging of transposed ovaries in patients with cervical carcinoma. AJR: American Journal of Roentgenology. 2005;184(5):1602-1610. https://doi.org/10.2214/ajr.184.5.01841602
  62. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of «untreated» hyperplasia in 170 patients. Cancer. 1985;56(2):403-412.  https://doi.org/10.1002/1097-0142(19850715)56:2<403::aid-cncr2820560233>3.0.co;2-x
  63. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ 2nd, Alberts D, Curtin J. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006;106(4):812-819.  https://doi.org/10.1002/cncr.21650
  64. Chulkova OV, Novikova EG, Pronin SM. Organ-preserving and functionally sparing treatment of endometrial cancer. Opuxoli zhenskoj reproduktivnoj sistemyt. 2007;1-2:50-57. (In Russ.).
  65. Boxman YaV, Pryanishnikov VA, Chepik OF. Kompleksnoe lechenie pri giperplasticheskix processax i rake etndometriya. M.: Medicina; 1979. (In Russ.).
  66. Gallos ID, Yap J, Rajkhowa M, Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. American Journal of Obstetrics and Gynecology. 2012;207:266.e1-12. 
  67. Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecologic Oncology. 2012;125:477. 
  68. Guillon S, Popescu N, Phelippea J, Koskas M. A systematic review and meta- analysis of prognostic factors for remission in fertility-sparing management of en- dometrial atypical hyperplasia and adenocarcinoma, International Journal of Gynecology and Obstetrics. 2019;146(3):277-288. 
  69. Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T.Tissue concentrations of levonorgesrel in women using a levonorgestrel-releasing IUD. Clinical Endocrinology. 1982;17(6):529-536.  https://doi.org/10.1111/j.1365-2265.1982.tb01625.x
  70. Novikova OV, Nosov VB, Panov VA, Novikova EG, Krasnopolskaya KV, Andreeva YY, Shevchuk AS. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer. Gynecologic Oncology. 2021;161(1):152-159.  https://doi.org/10.1016/j.ygyno.2021.01.001
  71. Zaino R, Whitney C, Brady MF, DeGeest K, Burger RA, Buller RE. Simultaneously detected endometrial and ovarian carcinomas — prospective clinicopathologic study of 74 cases: a gynecologic oncology group study. Gynecologic Oncology. 2001;83(2): 355-362.  https://doi.org/10.1006/gyno.2001.6400
  72. Schultheis AM, Ng CK, De Filippo MR, Piscuoglio S, Macedo GS, Gatius S, Perez Mies B, Soslow RA, Lim RS, Viale A, Huberman KH, Palacios JC, Reis-Filho JS, Matias-Guiu X, Weigelt B. Massively parallel sequencing-based clonality analysis of synchronous endometrioid endometrial and ovarian carcinomas. Journal of the National Cancer Institute. 2016;108(6):djv427. https://doi.org/10.1093/jnci/djv427
  73. Jordania KI, Payanidi YuG, Loginov VI, Chemeris GYu, Adamyan LV. Synchronous endometrioid tumors of the uterus and ovaries. Difficulties of interpretation. Problemyt reprodukcii. 2018;24(4):66-70. (In Russ.).
  74. Turashvili G, Gómez-Hidalgo NR, Flynn J, Gonen M, Leitao MM Jr, Soslow RA, Murali R. Risk-based stratification of carcinomas concurrently involving the endometrium and ovary. Gynecologic Oncology. 2019;152(1):38-45.  https://doi.org/10.1016/j.ygyno.2018.10.033
  75. Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, Lindemann K, Mutch D, Concin N; Endometrial Cancer Staging Subcommittee, FIGO Women’s Cancer Committee. FIGO staging of endometrial cancer: 2023. International Journal of Gynecology and Obstetrics. 2023;162:383-394.  https://doi.org/10.1002/ijgo.14923
  76. Acs G. Serous and mucinous borderline (low malignant potential) tumors of the ovary. American Journal of Clinical Pathology. 2005; 123(suppl):S13-S57.  https://doi.org/10.1309/J6PXXK1HQJAEBVPM
  77. Swanton A, Bankhead CR, Kehoe S. Pregnancy rates after conservative treatment for borderline ovarian tumours: a systematic review. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2007;135:3-7. 
  78. Seidman AJ, Varallo MR. Micropapillary serous carcinoma: The solution to the ovarian borderline tumor conundrum. Pathology Case Reviews. 2007;12:136-142. 
  79. Lalwani N, Shanbhogue AK, Vikram R, Nagar A, Jagirdar J, Prasad SR. Current Update on Borderline Ovarian Neoplasms. AJR. American Journal of Roentgenology. 2010;194(2):330-336.  https://doi.org/10.2214/AJR.09.3936
  80. Tropé C, Davidson B, Paulsen T, Abeler VM, Kaern J. Diagnosis and treatment of borderline ovarian neoplasms «the state of the art». European Journal of Gynaecological Oncology. 2009;30(5):471-482. 
  81. Seidman JD, Kurman RJ. Ovarian serous borderline tumors: A critical review of the literature with emphasis on prognostic indicators. Human Pathology. 2000;31(5):539-557.  https://doi.org/10.1053/hp.2000.8048
  82. Canlorbe G, Chabbert-Buffet N, Uzan C. Fertility-Sparing Surgery for Ovarian Cancer. Journal of Clinical Medicine. 2021;10(18):4235. https://doi.org/10.3390/jcm10184235
  83. Daraï E, Fauvet R, Uzan C, Gouy S, Duvillard P, Morice P. Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options. Human Reproduction Update. 2013;19(2):151-166.  https://doi.org/10.1093/humupd/dms047
  84. du Bois A, Ewald-Riegler N, de Gregorio N, et al. Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group. European Journal of Cancer. 2013;49(8):1905-1914. https://doi.org/10.1016/j.ejca.2013.01.035
  85. Morice P. Borderline tumours of the ovary and fertility European Journal of Cancer. 2006;42(2):149-158.  https://doi.org/10.1016/j.ejca.2005.07.029
  86. Suh-Burgmann E. Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study. Gynecologic Oncology. 2006;103(3):841-844.  https://doi.org/10.1016/j.ygyno.2006.05.014
  87. Lavrinovich O, Yakovleva M, Berlev I, Urmancheeva A. Fertility preservation in patients with malignant and borderline ovarian tumors. Voprosy onkologii. 2021;67(4):547-553. (In Russ.). https://doi.org/10.37469/0507-3758-2021-67-4-547-553
  88. Kasaven LS, Chawla M, Jones BP, Al-Memar M, Galazis N, Ahmed-Salim Y, El-Bahrawy M, Lavery S, Saso S, Yazbek J. Fertility Sparing Surgery and Borderline Ovarian Tumours. Cancers. 2022;14(6):1485. https://doi.org/10.3390/cancers14061485
  89. Tinelli R, Tinelli A, Tinelli FG, Cicinelli E, Malvasi A. Conservative surgery for borderline ovarian tumors: a review. Gynecologic Oncology. 2006;100(1):185-191.  https://doi.org/10.1016/j.ygyno.2005.09.021
  90. Trillsch F, Mahner S, Ruetzel J, Harter P, Ewald-Riegler N, Jaenicke F, du Bois A. Clinical management of borderline ovarian tumors. Expert Review of Anticancer Therapy. 2010;10(7):1115-1124. https://doi.org/10.1586/era.10.90
  91. Seidman JD, Cho KR, Ronnett BM, Kurman RJ. Surface epithelial tumors of the ovary. In: Kurman RJ, Ellenson LH, Ronnett BM, eds. Blaustein′s Pathology of the Female Genital Tract. 6th ed. New York: Springer Science, Business Medica; 2011: 680-772.  https://doi.org/10.1007/978-1-4419-0489-8_14
  92. Kurman RJ, Trimble CL. The behavior of serous tumors of low malignant potential: are they ever malignant? International Journal of Gynecological Pathology. 1993;12(2):120-127.  https://doi.org/10.1097/00004347-199304000-00006
  93. Tavassoli FA, Devilee P. World Health Organization classification of tumors: pathology and genetics of tumors of the breast and female genital organs. Lyon, France: IARC Press; 2003.
  94. Frolova MA, Stenina MB, Glazkova EV, Ignatova EO, Menshikova SF, Petrovsky AV, Krokhina OV, Vishnevskaya YaV, Tyulyandin SA. Prognostic value of biological characteristics of a residual tumor after neoadjuvant chemotherapy in early breast cancer with a triple negative phenotype. Rossijskoe obshhestvo klinicheskoj onkologii. 2019;9(3):2. (In Russ.).
  95. Melamed A, Rizzo AE, Nitecki R, Gockley AA, Bregar AJ, Schorge JO, Del Carmen MG, Rauh-Hain JA. All-Cause Mortality After Fertility-Sparing Surgery for Stage I Epithelial Ovarian Cancer. Obstetrics and Gynecology. 2017;130(1):71-79.  https://doi.org/10.1097/AOG.0000000000002102
  96. Liu D, Cai J, Gao A, Wang Z, Cai L. Fertility sparing surgery vs radical surgery for epithelial ovarian cancer: A meta-analysis of overall survival and disease-free survival. BMC Cancer. 2020;20(1):320.  https://doi.org/10.1186/s12885-020-06828-y
  97. NCCN Guidelines. Ovarian Cancer. Version 2. 2023. Accessed January 17, 2024. https://livefund.ru/wp-content/uploads/2023/10/YAichniki.pdf?ysclid=lryrss5h8t401617320
  98. Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC.Hormonal Maintenance Therapy for Women with Low-Grade Serous C ancer of the Ovary or Peritoneum. Journal of Clinical Oncology. 2017;35(10):1103-1111. https://doi.org/10.1200/JCO.2016.71.0632
  99. Gnant M, Frantal S, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, WetteV, Balic M, Haslbauer F, Melbinger-Zeinitzer E, Bjelic Radisic V, Artner-Matuschek S, Kainberger F, Ritter M, Rinnerthaler G, Sevelda P, Bergh J, Kacerovsky-Strobl S, Suppan C, Brunner C, Deutschmann C, Gampenrieder SP, Fohler H, Raimund Jakesz MVM, Fesl C, Singer C, for the Austrian Breast and Colorectal Cancer Study Group. Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer. The New England Journal of Medicine. 2022;1(12). https://doi.org/10.1200/JCO.2022.40.16_suppl.507
  100. Fruscio R, Corso S, Ceppi L, Garavaglia D, Garbi A, Floriani I, Franchi D, Cantù MG, Bonazzi CM, Milani R, Mangioni C, Colombo N. Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series. Annals of Oncology. 2013;24(1):138-144.  https://doi.org/10.1093/annonc/mds241
  101. Fruscio R, Ceppi L, Corso S, Galli F, Dell’Anna T, Dell’Orto F, Giuliani D, Garbi A, Chiari S, Mangioni C, Milani R, Floriani I, Colombo N, Bonazzi CM. Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer. British Journal of Cancer. 2016;115(6): 641-648.  https://doi.org/10.1038/bjc.2016.254
  102. Kim J, Turan V, Oktay K. Long-Term Safety of Letrozole and Gonadotropin Stimulation for Fertility Preservation in Women with Breast Cancer. The Journal of Clinical Endocrinology and Metabolism. 2016;101(4):1364-1371. https://doi.org/10.1210/jc.2015-3878
  103. Nosov V, Silva I, Tavassoli F, Adamyan L, Farias-Eisner R, Schwartz PE. Predictors of recurrence of ovarian granulosa cell tumors. International Journal of Gynecological Cancer. 2009;19(4):628-633.  https://doi.org/10.1111/IGC.0b013e3181a48a6f
  104. Zhang M, Cheung MK, Shin JY, Kapp D, Husain A, Teng NN, Berek JS, Osann K, Chan JK. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary: an analysis of 376 women. Gynecologic Oncology. 2006;104(2):396-400.  https://doi.org/10.1016/j.ygyno.2006.08.032
  105. Park JY, Jin KL, Kim DY, Kim JH, Kim YM, Kim KR, Kim YT, Nam JH. Surgical staging and adjuvant chemotherapy in the management of patients with adult granulosa cell tumors of the ovary. Gynecologic Oncology. 2011;125(1):80-86.  https://doi.org/10.1016/j.ygyno.2011.12.442
  106. Iavazzo C, Gkegkes ID, Vrachnis N. Fertility sparing management and pregnancy in patients with granulosa cell tumour of the ovaries. Journal of Obstetrics and Gynaecology. 2014;35(4):331-335.  https://doi.org/10.3109/01443615.2014.968107
  107. Wang D, Cao D, Jia C, Huang H, Yang J, Wu M, Pan L, Shen K, Xiang Y. Analysis of oncologic and reproductive outcomes after fertility-sparing surgery in apparent stage I adult ovarian granulosa cell tumors. Gynecologic Oncology. 2018;151(2):275-281.  https://doi.org/10.1016/j.ygyno.2018.09.004
  108. Solheim O, Gershenson DM, Tropé CG, Rokkones E, Sun CC, Weedon-Fekjaer H, Fosså SD. Prognostic factors in malignant ovarian germ cell tumours (The Surveillance, Epidemiology and End Results experience 1978-2010). European Journal of Cancer. 2014; 50(11):1942-1950. https://doi.org/10.1016/j.ejca.2014.03.288
  109. Smith HO, Berwick M, Verschraegen CF, Wiggins C, Lansing L, Muller CY, Qualls CR. Incidence and survival rates for female malignant germ cell tumors. Obstetrics and Gynecology. 2006;107(5): 1075-1085. https://doi.org/10.1097/01.AOG.0000216004.22588.ce
  110. De Palo G, Pilotti S, Kenda R, Ratti E, Musumeci R, Mangioni C, Di Re F, Lattuada A, Conti U, Cefis F, Recanatini L, Carinelli S, Rossi G. Natural history of dysgerminoma. American Journal of Obstetrics and Gynecology. 1982;143(7):799-807.  https://doi.org/10.1016/0002-9378(82)90013-8
  111. Klinicheskie rekomendacii. Neetpitelialtnyte opuxoli yaichnikov. Odobreno Nauchno-prakticheskim Sovetom Ministerstva zdravooxraneniya Rossijskoj Federacii. 2020. Accessed January 17, 2024. (In Russ.). https://disuria.ru/_ld/13/1353_kr20C56MZ.pdf
  112. Mahdi H, Swensen RE, Hanna R, Kumar S, Ali-Fehmi R, Semaan A, Tamimi H, Morris RT, Munkarah AR. Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary. British Journal of Cancer. 2011;105(4):493-497.  https://doi.org/10.1038/bjc.2011.267
  113. Turkmen O, Karalok A, Basaran D, Kimyon GC, Tasci T, Ureyen I, Tulunay G, Turan T. Fertility-Sparing Surgery Should Be the Standard Treatment in Patients with Malignant Ovarian Germ Cell Tumors. Journal of Adolescent and Young Adult Oncology. 2017;6(2): 270-276.  https://doi.org/10.1089/jayao.2016.0086
  114. Talukdar S, Kumar S, Bhatla N, Mathur S, Thulkar S, Kumar L. Neo-adjuvant chemotherapy in the treatment of advanced malignant germ cell tumors of ovary. Gynecologic Oncology. 2014;132(1): 28-32.  https://doi.org/10.1016/j.ygyno.2013.10.009
  115. Peccatori F, Bonazzi C, Chiari S, Landoni F, Colombo N, Mangioni C. Surgical management of malignant ovarian germ-cell tumors: 10 years’ experience of 129 patients. Obstetrics and Gynecology.1995;86(3):367-372.  https://doi.org/10.1016/0029-7844(95)00192-T
  116. Gadducci A, Lanfredini N, Tana R. Menstrual function and childbearing potential after fertility-sparing surgery and platinum-based chemotherapy for malignant ovarian germ cell tumours. Gynecological Endocrinology. 2014;30(7):467-471.  https://doi.org/10.3109/09513590.2014.907262
  117. Yang B, Yu Y, Chen J, Zhang Y, Yin Y, Yu N, Chen G, Zhu S, Huang H, Yuan Y, Ai J, Wang X, Li K. Possibility of women treated with fertility-sparing surgery for non-epithelial ovarian tumors to safely and successfully become pregnant-a Chinese retrospective cohort study among 148 cases. Frontiers of Medicine. 2018;12(5): 509-517.  https://doi.org/10.1007/s11684-017-0554-3
  118. Solheim O, Tropé CG, Rokkones E, Kærn J, Paulsen T, Salvesen HB, Hagen B, Vereide AB, Fosså SD. Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the “cisplatin era”. Gynecologic Oncology. 2015;136(2):224-229.  https://doi.org/10.1016/j.ygyno.2014.12.010
  119. Tamauchi S, Kajiyama H, Yoshihara M, Ikeda Y, Yoshikawa N, Nishino K, Utsumi F, Niimi K, Suzuki S, Kikkawa F. Reproductive outcomes of 105 malignant ovarian germ cell tumor survivors: a multicenter study. American Journal of Obstetrics and Gynecology. 2018;219(4):385.e1-385.e7.  https://doi.org/10.1016/j.ajog.2018.07.021
  120. Tomao F, Di Pinto A, Sassu CM, Bardhi E, Di Donato V, Muzii L, Petrella MC, Peccatori FA, Panici PB. Fertility preservation in ovarian tumours. Ecancermedicalscience. 2018;12:885.  https://doi.org/10.3332/ecancer.2018.885
  121. Partridge AH, Niman SM, Ruggeri M, et.al. International Breast Cancer Study Group; POSITIVE Trial Collaborators. Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer. New England Journal of Medicine. 2023;388(18):1645-1656.
  122. American Cancer Society. Accessed January 17, 2024. https://www.cancer.org/cancer/survivorship/long-term-health-concerns/pregnancy-after-cancer.html
  123. Hartman EK, Eslick GD. The prognosis of women diagnosed with breast cancer before, during and after pregnancy: a meta-analysis. Breast Cancer Research and Treatment. 2016;160(2):347-360.  https://doi.org/10.1007/s10549-016-3989-3
  124. Khazzaka A, Rassy E, Sleiman Z, Boussios S, Pavlidis N. Systematic review of fetal and placental metastases among pregnant patients with cancer. Cancer Treatment Reviews. 2022;104:102356. https://doi.org/10.1016/j.ctrv.2022.102356
  125. National Cancer Insitute. Accessed January 17, 2024. https://www.cancer.gov/about-cancer/causes-prevention/genetics/
  126. Michaan N, Leshno M, Cohen Y, Safra T, Peleg-Hasson S, Laskov I, Grisaru D. Preimplantation genetic testing for BRCA gene mutation carriers: a cost effectiveness analysis. Reproductive Biology and Endocrinology. 2021;19(1):153.  https://doi.org/10.1186/s12958-021-00827-9
  127. Hartnett KP, Mertens AC, Kramer MR, Lash TL, Spencer JB, Ward KC, Howards PP. Pregnancy after cancer: Does timing of conception affect infant health? Cancer. 2018;124(22):4401-4407. https://doi.org/10.1002/cncr.31732
  128. Buonomo B, Brunello A, Noli S, Miglietta L, Del Mastro L, Lambertini M, Peccatori FA. Tamoxifen Exposure during Pregnancy: A Systematic Review and Three More Cases. Breast Care. 2020;15(2): 148-156.  https://doi.org/10.1159/000501473
  129. Braems G, Denys H, De Wever O, Cocquyt V, Van den Broecke R. Use of tamoxifen before and during pregnancy. The Oncologist. 2011;16(11):1547-51.  https://doi.org/10.1634/theoncologist.2011-0121
  130. Egashira K, Hiasa K, Yokota N, Kawamura T, Matsushita T, Okugawa K, Yahata H, Sonoda K, Kato K. Infertility after abdominal trachelectomy. Acta Obstetricia et Gynecologica Scandinavica. 2018; 97(11):1358-1364. https://doi.org/10.1111/aogs.13429
  131. Schimberni M, Morgia F, Colabianchi J, Giallonardo A, Piscitelli C, Giannini P, Montigiani M, Sbracia M. Natural-cycle in vitro fertilization in poor responder patients: a survey of 500 consecutive cycles. Fertility and Sterility. 2009;92(4):1297-1301. https://doi.org/10.1016/j.fertnstert.2008.07.1765
  132. De Marco MP, Montanari G, Ruscito I, Giallonardo A, Ubaldi FM, Rienzi L, Costanzi F, Caserta D, Schimberni M, Schimberni M. Natural Cycle Results in Lower Implantation Failure than Ovarian Stimulation in Advanced-Age Poor Responders Undergoing IVF: Fertility Outcomes from 585 Patients. Reproductive Sciences. 2021; 28(7):1967-1973. https://doi.org/10.1007/s43032-020-00455-5
  133. Chan JL, Johnson LN, Efymow BL, Sammel MD, Gracia CR. Outcomes of ovarian stimulation after treatment with chemotherapy. Journal of Assisted Reproduction and Genetics. 2015;32(10):1537-1545. https://doi.org/10.1007/s10815-015-0575-2
  134. Checa Vizcaíno MA, Corchado AR, Cuadri ME, Comadran MG, Brassesco M, Carreras R. The effects of letrozole on ovarian stimulation for fertility preservation in cancer-affected women. Reproductive Biomedicine Online. 2012;24(6):606-610.  https://doi.org/10.1016/j.rbmo.2012.02.020
  135. Oktay K, Türkçüoğlu I, Rodriguez-Wallberg KA. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reproductive Biomedicine Online. 2010;20(6):783-788.  https://doi.org/10.1016/j.rbmo.2010.03.004
  136. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. Journal of Clinical Oncology. 2008;26(16):2630-2635. https://doi.org/10.1200/JCO.2007.14.8700
  137. Turan V, Bedoschi G, Moy F, Oktay K. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients. Fertility and Sterility. 2013;100(6):1681-5.e1.  https://doi.org/10.1016/j.fertnstert.2013.08.030
  138. Rosenberg E, Fredriksson A, Einbeigi Z, Bergh C, Strandell A. No increased risk of relapse of breast cancer for women who give birth after assisted conception. Human Reproduction Open. 2019;(4): hoz039. https://doi.org/10.1093/hropen/hoz039
  139. Sonigo C, Sermondade N, Calvo J, Benard J, Sifer C, Grynberg M. Impact of letrozole supplementation during ovarian stimulation for fertility preservation in breast cancer patients. European Journal of Obstetrics and Gynecology and Reproductive Biology. 2019;4:100049. https://doi.org/10.1016/j.eurox.2019.100049
  140. Bonardi B, Massarotti C, Bruzzone M, Goldrat O, Mangili G, Anserini P, Spinaci S, Arecco L, Del Mastro L, Ceppi M, Demeestere I, Lambertini M. Efficacy and Safety of Controlled Ovarian Stimulation With or Without Letrozole Co-administration for Fertility Preservation: A Systematic Review and Meta-Analysis. Frontiers in Oncology. 2020;10:574669. https://doi.org/10.3389/fonc.2020.574669
  141. Chian RC, Buckett WM, Tulandi T, Tan SL. Prospective randomized study of human chorionic gonadotrophin priming before immature oocyte retrieval from unstimulated women with polycystic ovarian syndrome. Human Reproduction. 2000;15(1):165-170.  https://doi.org/10.1093/humrep/15.1.165
  142. Holzer H, Scharf E, Chian RC, Demirtas E, Buckett W, Tan SL. In vitro maturation of oocytes collected from unstimulated ovaries for oocyte donation. Fertility and Sterility. 2007;88(1):62-67.  https://doi.org/10.1016/j.fertnstert.2006.11.087
  143. Kedem A, Yerushalmi GM, Brengauz M, Raanani H, Orvieto R, Hourvitz A, Meirow D. Outcome of immature oocytes collection of 119 cancer patients during ovarian tissue harvesting for fertility preservation. Journal of Assisted Reproduction and Genetics. 2018;35(5): 851-856.  https://doi.org/10.1007/s10815-018-1153-1
  144. Park CW, Lee SH, Yang KM, Lee IH, Lim KT, Lee KH, Kim TJ. Cryopreservation of in vitro matured oocytes after ex vivo oocyte retrieval from gynecologic cancer patients undergoing radical surgery. Clinical and Experimental Reproductive Medicine. 2016;43(2):119-125.  https://doi.org/10.5653/cerm.2016.43.2.119
  145. Kawamura K, Cheng Y, Kawamura N, Takae S, Okada A, Kawagoe Y, Mulders S, Terada Y, Hsueh AJ. Pre-ovulatory LH/hCG surge decreases C-type natriuretic peptide secretion by ovarian granulosa cells to promote meiotic resumption of pre-ovulatory oocytes. Human Reproduction. 2011;26(11):3094-3101. https://doi.org/10.1093/humrep/der282
  146. Mohsenzadeh M, Khalili MA, Tabibnejad N, Yari N, Agha-Rahimi A, Karimi-Zarchi M. Embryo Cryopreservation Following In-Vitro Maturation for Fertility Preservation in a Woman with Mullerian Adenosarcoma: A Case Report. Journal of Human Reproductive Sciences. 2017;10(2):138-141.  https://doi.org/10.4103/jhrs.JHRS_93_16
  147. Kirillova A, Bunyaeva E, Van Ranst H, Khabas G, Farmakovskaya M, Kamaletdinov N, Nazarenko T, Abubakirov A, Sukhikh G, Smitz JEJ. Improved maturation competence of ovarian tissue oocytes using a biphasic in vitro maturation system for patients with gynecological malignancy: a study on sibling oocytes. Journal of Assisted Reproduction and Genetics. 2021;38(6):1331-1340. https://doi.org/10.1007/s10815-021-02118-z
  148. Sanchez F, Le AH, Ho VNA, Romero S, Van Ranst H, De Vos M, Gilchrist RB, Ho TM, Vuong LN, Smitz J. Biphasic in vitro maturation (CAPA-IVM) specifically improves the developmental capacity of oocytes from small antral follicles. Journal of Assisted Reproduction and Genetics. 2019;36(10):2135-2144. https://doi.org/10.1007/s10815-019-01551-5
  149. De Roo C, Tilleman K. In Vitro Maturation of Oocytes Retrieved from Ovarian Tissue: Outcomes from Current Approaches and Future Perspectives. Journal of Clinical Medicine. 2021;10(20):4680. https://doi.org/10.3390/jcm10204680
  150. Dinikina YuV, Belogurova MB, Govorov IE, Gamzatova ZKh, Pervunina TM, Komlichenko EV. Cryopreservation of ovarian tissue in girls with oncological diseases: a multidisciplinary approach. Rossijskij zhurnal detskoj gematologii i onkologii. 2019;6(3):59-67.  https://doi.org/10.21682/2311-1267-2019-6-3-59-67
  151. Abakushina EV, Otoi T, Kaprin AD. Recovery options of reproductive function of cancer patients due to transplantation of cryopreserved ovarian tissue. Geny i kletki. 2015;10(1):18-27. (In Russ.).
  152. Gougeon A, Chainy GB. Morphometric studies of small follicles in ovaries of women at different ages. Journal of Reproduction and Fertility. 1987;81(2):433-442.  https://doi.org/10.1530/jrf.0.0810433
  153. Dolmans MM, von Wolff M, Poirot C, Diaz-Garcia C, Cacciottola L, Boissel N, Liebenthron J, Pellicer A, Donnez J, Andersen CY. Transplantation of cryopreserved ovarian tissue in a series of 285 women: a review of five leading European centers. Fertility and Sterility. 2021;115(5):1102-1115. https://doi.org/10.1016/j.fertnstert.2021.03.008
  154. Donnez J, Dolmans MM. Ovarian cortex transplantation: 60 reported live births brings the success and worldwide expansion of the technique towards routine clinical practice. Journal of Assisted Reproduction and Genetics. 2015;32(8):1167-1170. https://doi.org/10.1007/s10815-015-0544-9
  155. Roness H, Meirow D. Fertility preservation: Follicle reserve loss in ovarian tissue transplantation. Reproduction. 2019;158(5):F35-F44.  https://doi.org/10.1530/REP-19-0097
  156. Nisolle M, Casanas-Roux F, Qu J, Motta P, Donnez J. Histologic and ultrastructural evaluation of fresh and frozen-thawed human ovarian xenografts in nude mice. Fertility and Sterility. 2000;74(1): 122-129.  https://doi.org/10.1016/s0015-0282(00)00548-3
  157. Tanaka A, Nakamura H, Tabata Y, Fujimori Y, Kumasawa K, Kimura T. Effect of sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogels on frozen-thawed human ovarian tissue in a xenograft model. The Journal of Obstetrics and Gynaecology Research. 2018;44(10):1947-1955. https://doi.org/10.1111/jog.13726
  158. Wallace WH, Kelsey TW. Human ovarian reserve from conception to the menopause. PLoS One. 2010;5(1):e8772. https://doi.org/10.1371/journal.pone.0008772
  159. Dolmans MM, Marinescu C, Saussoy P, Van Langendonckt A, Amorim C, Donnez J. Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood. 2010;116(16):2908-2914. https://doi.org/10.1182/blood-2010-01-265751
  160. Diaz-Garcia C, Domingo J, Garcia-Velasco JA, Herraiz S, Mirabet V, Iniesta I, Cobo A, Remohí J, Pellicer A. Oocyte vitrification versus ovarian cortex transplantation in fertility preservation for adult women undergoing gonadotoxic treatments: a prospective cohort study. Fertility and Sterility. 2018;109(3):478-485.e2.  https://doi.org/10.1016/j.fertnstert.2017.11.018
  161. Arvold ND, Taghian AG, Niemierko A, Abi Raad RF, Sreedhara M, Nguyen PL, Bellon JR, Wong JS, Smith BL, Harris JR. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. Journal of Clinical Oncology. 2011;29(29): 3885-3891. https://doi.org/10.1200/JCO.2011.36.1105
  162. Gellert SE, Pors SE, Kristensen SG, Bay-Bjørn AM, Ernst E, Yding Andersen C. Transplantation of frozen-thawed ovarian tissue: an update on worldwide activity published in peer-reviewed papers and on the Danish cohort. Journal of Assisted Reproduction and Genetics. 2018;35(4):561-570.  https://doi.org/10.1007/s10815-018-1144-2
  163. Salim N, Tumanova K, Stolbovoy A, Zvereva D, Popodko A Nosov V. Adaptive VMAT Radiotherapy to Avoid Brachytherapy in Cervical Cancer Treatment. International Journal of Radiation Oncology and Biology and Physics. 2022;114(supp 3):e262.
  164. Bystrova O, Lapina E, Kalugina A, Lisyanskaya A, Tapilskaya N, Manikhas G. Heterotopic transplantation of cryopreserved ovarian tissue in cancer patients: a case series. Gynecological Endocrinology. 2019;35(12):1043-1049. https://doi.org/10.1080/09513590.2019.1648413
  165. Donnez J. Chemotherapy and decline of the ovarian reserve: How can we explain it and how to prevent it? Fertility and Sterility. 2020; 114(4):722-724.  https://doi.org/10.1016/j.fertnstert.2020.08.010
  166. ESHRE Guideline Group on Female Fertility Preservation; Anderson RA, Amant F, Braat D, D’Angelo A, Chuva de Sousa Lopes SM, Demeestere I, Dwek S, Frith L, Lambertini M, Maslin C, Moura-Ramos M, Nogueira D, Rodriguez-Wallberg K, Vermeulen N. ESHRE guideline: female fertility preservation. Human Reproduction Open. 2020;2020(4):hoaa052. https://doi.org/10.1093/hropen/hoaa052
  167. Kindinger LM, Kyrgiou M, MacIntyre DA, Cacciatore S, Yulia A, Cook J, Terzidou V, Teoh TG, Bennett PR. Preterm Birth Prevention Post-Conization: A Model of Cervical Length Screening with Targeted Cerclage. PLoS One. 2016;11(11):e0163793. https://doi.org/10.1371/journal.pone.0163793
  168. Kyrgiou M, Athanasiou A, Paraskevaidi M, Mitra A, Kalliala I, Martin-Hirsch P, Arbyn M, Bennett P, Paraskevaidis E. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ. 2016;354:i3633. https://doi.org/10.1136/bmj.i3633
  169. Li X, Li J, Wu X. Incidence, risk factors and treatment of cervical stenosis after radical trachelectomy: A systematic review. European Journal of Cancer. 2015;51(13):1751-1759. https://doi.org/10.1016/j.ejca.2015.05.012
  170. Kasuga Y, Ikenoue S, Tanaka M, Ochiai D. Management of pregnancy after radical trachelectomy. Gynecological Oncology. 2021; 162(1):220-225.  https://doi.org/10.1016/j.ygyno.2021.04.023
  171. Šimják P, Cibula D, Pařízek A, Sláma J. Management of pregnancy after fertility-sparing surgery for cervical cancer. Acta Obstetricia et Gynecologica Scandinavia. 2020;99(7):830-838.  https://doi.org/10.1111/aogs.13917
  172. Sato Y, Hidaka N, Sakai A, Kido S, Fujita Y, Okugawa K, Yahata H, Kato K. Evaluation of the efficacy of vaginal progesterone in preventing preterm birth after abdominal trachelectomy. European Journal of Obstetrics Gynecology and Reproducive Biology. 2021;259: 119-124.  https://doi.org/10.1016/j.ejogrb.2021.02.009
  173. Signorello LB, Cohen SS, Bosetti C, Stovall M, Kasper CE, Weathers RE, Whitton JA, Green DM, Donaldson SS, Mertens AC, Robison LL, Boice JD Jr. Female survivors of childhood cancer: preterm birth and low birth weight among their children. Journal of National Cancer Institute. 2006;98(20):1453-1461. https://doi.org/10.1093/jnci/djj394
  174. Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. Journal of Clinical Oncology. 2003;21(6):1180-1189. https://doi.org/10.1200/JCO.2003.10.019
  175. Spanos CP, Mamopoulos A, Tsapas A, Syrakos T, Kiskinis D. Female fertility and colorectal cancer. International Journal of Colorectal Diseases. 2008;23(8):735-743.  https://doi.org/10.1007/s00384-008-0483-3
  176. Lopategui DM, Yechieli R, Ramasamy R. Oncofertility in sarcoma patients. Translational Andrology and Urology. 2017;6(5):951-958.  https://doi.org/10.21037/tau.2017.07.03
  177. Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertility and Sterility. 2013;99(1):37-43.  https://doi.org/10.1016/j.fertnstert.2012.09.028
  178. Akhmedova ZB, Umarova SG, Ashurova MJ. Fertility and Hodgkin’s lymphoma. Vestnik Avicennyt. 2013;(2):167-172. (In Russ.).
  179. Hodgson DC, Pintilie M, Gitterman L, Dewitt B, Buckley CA, Ahmed S, Smith K, Schwartz A, Tsang RW, Crump M, Wells W, Sun A, Gospodarowicz MK. Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematological Oncology. 2007;25(1):11-15.  https://doi.org/10.1002/hon.802
  180. Watson M, Wheatley K, Harrison GA, Zittoun R, Gray RG, Goldstone AH, Burnett AK. Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: analysis of the MRC AML 10 trial. Cancer. 1999;86(7):1231-1239. https://doi.org/10.1002/(sici)1097-0142(19991001)86:7<1231::aid-cncr18>3.0.co;2-y

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.